Abstract

Background

In a multicenter study from Taiwan, we aimed to investigate the outcome of patients who received different antimicrobial therapy in carbapenem-resistant Enterobacteriaceae bloodstream infections and proposed a new definition for tigecycline use.

Methods

Patients from 16 hospitals in Taiwan who received appropriate therapy for bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae and Escherichia coli were enrolled in the study between January 2012 and June 2015. We used a cox proportional regression model for multivariate analysis to identify independent risk factors of 14-day mortality. Tigecycline was defined as appropriate when the isolates had a minimum inhibitory concentration (MIC) ≤0.5 mg/L, and we investigated whether tigecycline was associated with mortality among patients with monotherapy.

Results

Sixty-four cases with carbapenem-resistant K pneumoniae (n = 50) and E coli (n = 14) bloodstream infections were analyzed. Of the 64 isolates, 17 (26.6%) had genes that encoded carbapenemases. The 14-day mortality of these cases was 31.3%. In the multivariate analysis, Charlson Comorbidity Index (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03–1.42; P = .022) and colistin monotherapy (HR, 5.57; 95% CI, 2.13–14.61; P < .001) were independently associated with 14-day mortality. Among the 55 patients with monotherapy, the 14-day mortality was 30.9% (n = 17). Tigecycline use was not associated with mortality in the multivariate analysis.

Conclusions

Tigecycline monotherapy was a choice if the strains exhibited MIC ≤0.5 mg/L, and colistin monotherapy was not suitable. Our findings can initiate additional clinical studies regarding the efficacy of tigecycline in carbapenem-resistant Enterobacteriaceae infections.

Details

Title
Appropriate Treatment for Bloodstream Infections Due to Carbapenem-Resistant Klebsiella pneumoniae and Escherichia coli: A Nationwide Multicenter Study in Taiwan
Author
Yi-Tsung, Lin 1 ; Chin-Fang, Su 2 ; Chuang, Chien 3 ; Jung-Chung, Lin 4 ; Po-Liang, Lu 5 ; Ching-Tai, Huang 6 ; Jann-Tay Wang 7 ; Yin-Ching, Chuang 8 ; Siu, L Kristopher 9 ; Chang-Phone Fung 10 

 Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taiwan; Institute of Emergency and Critical Care Medicine, National Yang-Ming University, Taipei, Taiwan 
 Division of Allergy, Immunology and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taiwan 
 Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taiwan 
 Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Centre, Taipei, Taiwan 
 Department of Internal Medicine, Kaohsiung Medical University Hospital, and College of Medicine, Kaohsiung Medical University, Taiwan 
 Division of Infectious Diseases, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan 
 Division of Infectious Diseases, Department of Medicine, National Taiwan University Hospital, Taipei 
 Department of Internal Medicine and Medical Research, Chi Mei Medical Centre, Tainan, Taiwan 
 Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan 
10  Division of Infectious Diseases, Sijhih Cathy General Hospital, New Taipei City, Taiwan 
Publication year
2019
Publication date
Feb 2019
Publisher
Oxford University Press
e-ISSN
23288957
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3170949804
Copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.